Ngā hua rapu - Jonas Kulhavy

Outcome of First-Line Treatment With Pembrolizumab According to KRAS/TP53 Mutational Status for Nonsquamous Programmed Death-Ligand 1–High (≥50%) NSCLC in the German National Netwo... mā Philip Bischoff, Martin Reck, Tobias R. Overbeck, Petros Christopoulos, Achim Rittmeyer, H Lüders, Jens Kollmeier, Jonas Kulhavy, Marcel Kemper, Niels Reinmuth, J Roper, Melanie Janning, Linna Sommer, Lukas Aguinarte, Myriam Koch, Marcel Wiesweg, Claas Wesseler, Cornelius F. Waller, Diego Kauffmann‐Guerrero, Albrecht Stenzinger, Susann Stephan-Falkenau, Marcel Trautmann, Silke Laßmann, Markus Tiemann, Frederick Klauschen, Martin Sebastian, Frank Griesinger, Jürgen Wolf, Sonja Loges, Nikolaj Frost, Moritz Hilbrandt, Juliane Süptitz, Christian Grah, Janna-Lisa Velthaus, Hans‐Georg Kopp, Bernd Schmidt, Susanne Horter, Stefanie Keymel, Enver Aydilek, Guergana Tritchkova, Matthias Raspe, Dražen Papić, Stefan Florian, David Horst, Peter J. Wild, Michael Thomas, Christian Grohé, Annalen Bleckmann, Martin Wermke, Horst-Dieter Hummel, Jan A. Stratmann, Wolfgang Schütte